At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 605 enrolled
Drug / intervention
Daclatasvir +3 moredrug
Likely dose
Daclatasvir 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
In Brief
A Phase 3 clinical trial evaluating Daclatasvir, Telaprevir, and 2 other interventions for Hepatitis C. Completed, enrolled 605 participants across 91 sites in 16 countries.
Detailed Summary
The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesArgentina, Australia, Austria, Brazil, Canada, Denmark, France, Germany, Israel, Italy, Poland, Russia, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartJan 2012
Primary CompletionDec 2013
Study CompletionMar 2014
TodayJul 2026
First PostedDec 15, 2011
Enrollment StartJan 1, 2012
Primary CompletionDec 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.5 years ago
Interventions
Daclatasvirdrug
Film-coated tablet, oral, 60 mg, once daily, 24 weeks
Telaprevirdrug
Film-coated tablet, oral, 750 mg, 3 times daily
Peginterferon alfa-2adrug
Solution for injection, subcutaneous injection, 180 μg, weekly
Ribavirindrug
Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day